Boral Anthony L. 4

4 · Blueprint Medicines Corp · Filed Sep 21, 2020

Form 4

Period: 2020-09-17

Sr. VP, Clinical Development

Transactions

Exercise/Conversion
Stock Option (Right to Buy)
2020-09-17−9,879→ 24,347 total
Exercise: $15.01Exp: 2026-02-03→ Common Stock (9,879 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2020-09-17−3,030→ 0 total
Exercise: $8.80Exp: 2025-02-10→ Common Stock (3,030 underlying)
Exercise/Conversion
Common Stock
2020-09-17$8.80/sh+3,030$26,664→ 31,873 total
Exercise/Conversion
Common Stock
2020-09-17$15.01/sh+9,879$148,284→ 28,843 total
Sale
Common Stock
2020-09-17$80.00/sh−23,136$1,850,880→ 18,964 total
Exercise/Conversion
Common Stock
2020-09-17$8.80/sh+10,227$89,998→ 42,100 total
Exercise/Conversion
Stock Option (Right to Buy)
2020-09-17−10,227→ 0 total
Exercise: $8.80Exp: 2025-02-10→ Common Stock (10,227 underlying)

Footnotes (4)

[F1]Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
[F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.05 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F3]This option was granted on February 3, 2016. This option is fully vested as of the date hereof.
[F4]This option was granted on February 10, 2015. This option is fully vested as of the date hereof.

Documents

1 file